- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Circulating tumor cells in breast cancer: clinical validity and utility ; volume:10 ; number:1 ; day:29 ; month:11 ; year:2024 ; pages:1-10 ; date:12.2024
npj Breast cancer ; 10, Heft 1 (29.11.2024), 1-10, 12.2024
- Creator
-
Thomas-Bonafos, Thibault
Pierga, Jean Yves
Bidard, François-Clément
Cabel, Luc
Kiavue, Nicolas
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-024-00706-7
- URN
-
urn:nbn:de:101:1-2502142104510.759383093842
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Thomas-Bonafos, Thibault
- Pierga, Jean Yves
- Bidard, François-Clément
- Cabel, Luc
- Kiavue, Nicolas
- SpringerLink (Online service)
Other Objects (12)
Circulating tumor DNA validity and potential uses in metastatic breast cancer
Circulating Tumor Cells in Early-Stage Breast Cancer
Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA
EMT-specific circulating micro RNAs and circulating tumor cells in metastatic breast cancer
Circulating tumor DNA: current implementation issues and future challenges for clinical utility
Circulating tumor cells in newly diagnosed inflammatory breast cancer
Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors
Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection
Minimal residual disease and circulating tumor cells in breast cancer
Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas
Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors
Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma
Circulating tumor DNA validity and potential uses in metastatic breast cancer
Circulating Tumor Cells in Early-Stage Breast Cancer
Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA
EMT-specific circulating micro RNAs and circulating tumor cells in metastatic breast cancer
Circulating tumor DNA: current implementation issues and future challenges for clinical utility
Circulating tumor cells in newly diagnosed inflammatory breast cancer
Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors
Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection
Minimal residual disease and circulating tumor cells in breast cancer
Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas
Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors
Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma
Circulating tumor DNA validity and potential uses in metastatic breast cancer
Circulating Tumor Cells in Early-Stage Breast Cancer
Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA
EMT-specific circulating micro RNAs and circulating tumor cells in metastatic breast cancer
Circulating tumor DNA: current implementation issues and future challenges for clinical utility
Circulating tumor cells in newly diagnosed inflammatory breast cancer
Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors
Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection
Minimal residual disease and circulating tumor cells in breast cancer
Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas
Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors